Answers are grounded in this paper and cite their sources.
Narcolepsy is a chronic neurological disease with substantial clinical, humanistic, and economic burden. Access to treatments varies across jurisdictions. This systematic review critically appraised the modeling approaches used in existing economic evaluations of treatments for narcolepsy and identified opportunities for improvements. Systematic literature searches were conducted in MEDLINE (Ovid), Embase, Cochrane Library, EconLit, and the International Network of Agencies for Health Technology Assessment database from inception to May 2026, supplemented by manual searches of major health technology assessment and other value assessment agency websites through June or July 2026. Trial-based or model-based cost-effectiveness, cost-utility, or cost-benefit analyses in adults with narcolepsy type 1 or 2 were eligible for inclusion, with no language or geographic restrictions. Information on model conceptualization, structure, inputs, uncertainty, validation, and transparency was extracted; quality was assessed using the Philips checklist. Seven economic evaluations were included. All were cost-utility models that shared a similar structure: an initial phase to determine treatment response, followed by a longer-term Markov model based on responder status, with treatment response extrapolated beyond the trial follow-up. Treatment benefit was primarily represented through changes in excessive daytime sleepiness, while other symptoms were omitted. Comparative efficacy was frequently based on expert opinion or individual trials rather than systematic and statistical evidence synthesis. Healthcare costs focused largely on drug acquisition, indirect costs were rarely incorporated, and downstream clinical and societal consequences were not directly modeled. Utility estimation relied on mapping algorithms from non-narcolepsy populations, different measures across treatments, or unclear sources. Sensitivity analyses focused predominantly on parameter uncertainty. Validation and transparency varied substantially across models. Published economic evaluations of narcolepsy treatments identified materially important aspects of the decision problem that were not incorporated into the models because of insufficient evidence, resulting in incomplete representation of the disease and the decision problem. Future evaluations require both appropriate model structures and evidence linking disease manifestations and treatment response to relevant outcomes, including downstream costs and consequences, alongside rigorous comparative evidence synthesis, utility values derived from people with narcolepsy, and comprehensive assessment of parameter, methodological, and structural uncertainty.
No takes yet. Share an insight, caveat, or question.
Bermingham et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: